Pure Global AI
NCT05940259Recruiting

68Ga-P3 PET/CT Imaging in Prostate

A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate
Peking University First HospitalClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Neoplasms
Drug/Device/Intervention
[68Ga]P3
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking University First Hospital
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
May 29, 2023
End date
Jul 31, 2025
Enrollment
30 participants
Primary outcome

The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate,The detection efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate

Summary

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that
 consists of 750 amino acids. It is highly expressed on most prostate cancer cells and
 neovascular endothelial cells of tumors, making PSMA a highly specific and significant
 imaging target for malignancies.
 
 [68Ga]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the
 diagnosis and research of a wide variety of PSMA high-expression malignanciesr.

ICD-10 classifications
NeoplasmsIn situ neoplasmsPersonal history of other neoplasmsBenign neoplasmsMalignant neoplasms
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05940259
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05940259 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University First Hospital and is currently Recruiting. The study focuses on Neoplasms. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.